Cargando…

Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy

Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Tefas, Lucia Ruxandra, Barbălată, Cristina, Tefas, Cristian, Tomuță, Ioan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401311/
https://www.ncbi.nlm.nih.gov/pubmed/34452081
http://dx.doi.org/10.3390/pharmaceutics13081120
_version_ 1783745520577019904
author Tefas, Lucia Ruxandra
Barbălată, Cristina
Tefas, Cristian
Tomuță, Ioan
author_facet Tefas, Lucia Ruxandra
Barbălată, Cristina
Tefas, Cristian
Tomuță, Ioan
author_sort Tefas, Lucia Ruxandra
collection PubMed
description Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, has emerged as a promising new candidate for cancer therapy, with selective cytotoxicity against CSCs in various malignancies. Nanotechnology provides an efficient means of delivering Sali to tumors in view of reducing collateral damage to healthy tissues and enhancing the therapeutic outcome. This review offers an insight into the most recent advances in cancer therapy using Sali-based nanocarriers.
format Online
Article
Text
id pubmed-8401311
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84013112021-08-29 Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy Tefas, Lucia Ruxandra Barbălată, Cristina Tefas, Cristian Tomuță, Ioan Pharmaceutics Review Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, has emerged as a promising new candidate for cancer therapy, with selective cytotoxicity against CSCs in various malignancies. Nanotechnology provides an efficient means of delivering Sali to tumors in view of reducing collateral damage to healthy tissues and enhancing the therapeutic outcome. This review offers an insight into the most recent advances in cancer therapy using Sali-based nanocarriers. MDPI 2021-07-22 /pmc/articles/PMC8401311/ /pubmed/34452081 http://dx.doi.org/10.3390/pharmaceutics13081120 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tefas, Lucia Ruxandra
Barbălată, Cristina
Tefas, Cristian
Tomuță, Ioan
Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
title Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
title_full Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
title_fullStr Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
title_full_unstemmed Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
title_short Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
title_sort salinomycin-based drug delivery systems: overcoming the hurdles in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401311/
https://www.ncbi.nlm.nih.gov/pubmed/34452081
http://dx.doi.org/10.3390/pharmaceutics13081120
work_keys_str_mv AT tefasluciaruxandra salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy
AT barbalatacristina salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy
AT tefascristian salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy
AT tomutaioan salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy